Alzheimer’s Disease Market Booming with Top 10 Players Worldwide by Therapeutics and Diagnostics Forecasts Till 2022

Alzheimer’s Disease Market
Global Alzheimer’s Disease Diagnostic Market Information, by Type (Early-onset Alzheimer’s, Late-onset Alzheimer’s, Familial Alzheimer’s disease), by Diagnostic test (Genetic testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging and others), by End Users (Clinics, Hospitals, Diagnostic Centers and others) – Forecast Till 2022

The Global Alzheimer’s Disease Market for this is expected to reach USD 12 billion by the end of the forecasted period growing at a CAGR of 10%.

Alzheimer’s is a type of dementia which results in memory loss accompanied by problem in thinking and behavior process. Alzheimer’s is a progressive disease as it gradually increases with time and damages maximum part of the brain finally destroying brain cells. It has been observed that maximum incidence of this disease is in UK where more than 520,000 people are diagnosed with Alzheimer’s disease and the increasing ageing population is the reason which is driving Alzheimer’s disease diagnostic and therapeutic market.

Alzheimer’s Disease Industry Segments:

The industry for Alzheimer’s Diseases globally on the basis of type has been segmented into late-onset Alzheimer’s disease, early-onset Alzheimer’s disease, familial Alzheimer’s disease and more. The end users category segments the market into hospitals, clinics, diagnostic centers and others. The diagnostic test segment of the industry comprises of mini-mental state exam (MMSE), genetic testing, neurological exam, brain imaging and others.

Get PDF Broacher of Alzheimer’s Disease Market Report spread across 90 Premium Pages, Top 7 Companies Profile and Supported with Respective Tables and Figures is Now Available at https://www.marketresearchfuture.com/sample_request/2149 .

Alzheimer’s Disease Market Detailed Regional Analysis

The regional analysis for Alzheimer’s Disease market includes regions such as Europe, Asia Pacific, North America and rest of the world. The North American region held the major market share in Alzheimer’s Disease globally in 2015. The North American region for Alzheimer’s Diseases is anticipated to reach USD 12 Million by the end of the forecast period. The European region is the second major industry for Alzheimer’s Disease industry. The Asia Pacific is estimated to be the most rapidly growing region of the Alzheimer’s Disease industry in the forecast period.

Global Alzheimer’s Disease Diagnostic Market – Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Alzheimer’s disease diagnostic appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among players.

Eli Lilly and Company is one of the major players in the global Alzheimer’s disease diagnostic market.  The total revenue generated by the company in 2016 was reported to be approximately around 21.2 billion. Followed by such huge revenue the company invested 24.7% of its revenue on the research and development. Following such a trends from the past few years, Eli Lilly and Company became a global leader in the fight against Alzheimer’s disease and it is leading the market since last 30 years. Today, Eli Lilly and Company has molecules to treat and diagnose Alzheimer’s disease in various stages of clinical development, including seven investigational compounds to treat Alzheimer’s disease and two diagnostics to help better diagnose the disease condition. To enhance the product development and commercialization the company in Jan. 27, 2016 announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.

Eli Lilly and Company. (U.S.), TauRx (Asia Pacific), Accera, Inc. (U.S.), Treventis Corporation. (U.S.), Neuro-Bio Ltd (Europe), CogRx (U.S.) are some of the prominent players at the forefront of competition in the Global Alzheimer’s disease diagnostic Market and are profiled in MRFR Analysis.

Major TCO For Global Alzheimer’s Disease Diagnostic Market Research Report- Forecast to 2022:

1 Introduction

1.1 Definition

1.2 Scope Of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power Of Suppliers

4.1.2 Bargaining Power Of Customer

4.1.3 Intensity Of Competitor’s

TOC Continued….!

Ask To Experts @ https://www.marketresearchfuture.com/enquiry/2149 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/alzheimers-disease-diagnostic-market-2149